Education
About Us
Working with TipRanks
Follow Us
Arcellx Inc (ACLX)
NASDAQ:ACLX
ACLX Stock Chart & Stats
$84.07
-$3.36(-4.36%)
At close: 4:00 PM EST
$84.07
-$3.36(-4.36%)
Day’s Range― - ―
52-Week Range$47.86 - $107.37
Previous CloseN/A
Volume227.93K
Average Volume (3M)548.08K
Market Cap
$4.62B
Enterprise Value$3.30B
Total Cash (Recent Filing)$453.10M
Total Debt (Recent Filing)$52.51M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Nov 17, 2025EPS Estimate
-0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding55,458,910
10 Day Avg. Volume581,506
30 Day Avg. Volume548,077
Financial Highlights & Ratios
PEG Ratio-1.06
Price to Book (P/B)9.03
Price to Sales (P/S)38.06
P/FCF Ratio-42.39
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue57.94
Enterprise Value/Gross Profit59.64
Enterprise Value/Ebitda-17.62
Forecast
1Y Price Target
$115.46Price Target Upside37.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Bulls Say, Bears Say
Bulls Say
Financial PositionArcellx currently holds approximately $538M cash to support the company into 2028 for key data readouts and anito-cel launch.
Product EfficacyThe trial achieved a high overall response rate of 97%, indicating strong potential for anito-cel's approval.
Safety ProfileNo delayed neurotoxicities were observed in the trial, highlighting the favorable safety profile of anito-cel.
Bears Say
Approval TimelineWaiting until Progression Free Survival data are mature is considered a better approach.
Arcellx Inc News
ACLX FAQ
What was Arcellx Inc’s price range in the past 12 months?
Arcellx Inc lowest stock price was $47.86 and its highest was $107.37 in the past 12 months.
What is Arcellx Inc’s market cap?
Arcellx Inc’s market cap is $4.62B.
When is Arcellx Inc’s upcoming earnings report date?
Arcellx Inc’s upcoming earnings report date is Nov 17, 2025 which is in 23 days.
How were Arcellx Inc’s earnings last quarter?
Arcellx Inc released its earnings results on Aug 07, 2025. The company reported -$0.94 earnings per share for the quarter, beating the consensus estimate of -$1.005 by $0.065.
Is Arcellx Inc overvalued?
According to Wall Street analysts Arcellx Inc’s price is currently Undervalued.
Does Arcellx Inc pay dividends?
Arcellx Inc does not currently pay dividends.
What is Arcellx Inc’s EPS estimate?
Arcellx Inc’s EPS estimate is -0.96.
How many shares outstanding does Arcellx Inc have?
Arcellx Inc has 55,458,910 shares outstanding.
What happened to Arcellx Inc’s price movement after its last earnings report?
Arcellx Inc reported an EPS of -$0.94 in its last earnings report, beating expectations of -$1.005. Following the earnings report the stock price went down -0.914%.
Which hedge fund is a major shareholder of Arcellx Inc?
Currently, no hedge funds are holding shares in ACLX
Arcellx Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$115.46 (37.34% Upside)
$115.46 (37.34% Upside)
Blogger Sentiment
Neutral
ACLX Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 216.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days >0.1%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.67%
12-Months-Change
Fundamentals
Return on Equity
-42.75%
Trailing 12-Months
Asset Growth
-15.69%
Trailing 12-Months
Company Description
Arcellx Inc
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
ACLX Stock 12 Month Forecast
Average Price Target
$115.46
▲(37.34% Upside)
Technical Analysis
Protagonist Therapeutics
―
Apellis Pharmaceuticals
―
Immunovant
―
Beam Therapeutics
―
MoonLake Immunotherapeutics
―
Ownership Overview
3.85% Insiders
27.47% Mutual Funds
0.06% Other Institutional Investors
54.40% Public Companies and Individual Investors